Status:
COMPLETED
A Study to Assess Safety and PK of Liquid Alpha₁-Proteinase Inhibitor (Human) in Treating Alpha₁-Antitrypsin Deficiency
Lead Sponsor:
Grifols Therapeutics LLC
Conditions:
Alpha₁-Antitrypsin Deficiency
Eligibility:
All Genders
18-70 years
Phase:
PHASE2
PHASE3
Brief Summary
Grifols Therapeutics Inc. conducted a multi-center, randomized, double-blind, crossover study to evaluate the safety, immunogenicity, and pharmacokinetics (PK) of Liquid Alpha₁-PI compared to the curr...
Eligibility Criteria
Inclusion
- Be between 18 and 70 years of age, inclusive
- Had a diagnosis of congenital AATD
- Had a documented total alpha₁-PI level \< 11 µM. If the total alpha₁-PI level had yet to be documented, a blood draw for total alpha₁-PI level was obtained at the Screening Visit
- Had a post-bronchodilator Forced expiratory volume in 1 second (FEV1) ≥ 30% and \< 80% of predicted and FEV1/forced vital capacity (FVC) \< 70%
- If the subject had received alpha₁-PI augmentation therapy of any kind, he/she must have been be willing to discontinue that treatment at the Week 1 (Baseline) Visit and remain off any kind of alpha₁-PI treatment, other than the investigational products for this study, while participating in the study
Exclusion
- Subject had a moderate or severe pulmonary exacerbation during the 4 weeks before the Week 1 (Baseline) Visit
- History of lung or liver transplant
- Any lung surgery during the past 2 years (excluding lung biopsy)
- Liver cirrhosis confirmed by biopsy
- Elevated liver enzymes (aspartate transaminase \[AST\], alanine aminotransferase \[ALT\], and alkaline phosphatase \[ALP\]) equal to or greater than 2.5 times the upper limit of normal
- Severe concomitant disease (e.g., congestive heart failure, clinically significant pulmonary fibrosis, malignant disease \[with the exception of skin cancers other than melanoma\], history of acute hypersensitivity pneumonitis reaction, or current chronic hypersensitivity pneumonitis)
- Females who were pregnant, breastfeeding or, if of child-bearing potential, unwilling to practice a highly effective method of contraception (oral, injectable or implanted hormonal methods of contraception, placement of an intrauterine device (IUD) or intrauterine system (IUS), condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or abstinence) throughout the study
- Known previous infection with or clinical signs and symptoms consistent with current hepatitis A virus (HAV), hepatitis B virus (HBV), hepatitis C virus (HCV), or human immunodeficiency virus (HIV) infection
- Smoking during the past 6 months or a positive urine cotinine test at the Screening Visit that is due to smoking
- Participation in another investigational drug study within one month prior to the Week 1 (Baseline) Visit
- History of anaphylaxis or severe systemic response to any plasma-derived alpha1-PI preparation or other blood product(s)
- Use of systemic steroids above a stable dose equivalent to 5 mg/day prednisone (i.e.,10 mg every 2 days) within the 4 weeks prior to the Week 1 (Baseline) Visit inhaled steroids are not considered systemic steroids)
- Use of systemic or aerosolized antibiotics for an exacerbation within the 4 weeks prior to the Week 1 (Baseline) Visit
- Known selective or severe Immunoglobulin A (IgA) deficiency
Key Trial Info
Start Date :
October 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2016
Estimated Enrollment :
32 Patients enrolled
Trial Details
Trial ID
NCT02282527
Start Date
October 1 2014
End Date
January 1 2016
Last Update
March 13 2017
Active Locations (6)
Enter a location and click search to find clinical trials sorted by distance.
1
National Jewish Health
Denver, Colorado, United States, 80206
2
University of Florida Gainesville
Gainesville, Florida, United States, 32610
3
University of Miami - Miller School of Medicine
Miami, Florida, United States, 33136
4
PMG Research of Wilmington
Wilmington, North Carolina, United States, 28401